JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 6 No. 3 196-204
© 1965 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, J. P.
Right arrow Articles by Crawford, L. E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, J. P.
Right arrow Articles by Crawford, L. E. M.

Internal Dosimetry Studies of Radiopharmaceuticals; II. Sodium Iodohippurate 131I1

Jonathan P. Miller, Ph.D., Ann Dalziel and L. E. Michael Crawford, B.S.2

North Chicago, Illinois

ABSTRACT

The distribution and effective half-life of Sodium Iodohippurate 131I has been studied in both rats and cats. These data have been extrapolated to man to estimate the radiation dose delivered during diagnostic use for determination of renal function. Radiation dosage calculations indicate that the radiation hazard from a 30 µc dose of Sodium Iodohippurate 131I would seem to be minimal, and that this dose would deliver less radiation than suggested weekly exposure limits to radiation workers.

FOOTNOTES

Hippuran®-131, Abbott Laboratories, North Chicago, Illinois, & Oak Ridge, Tennessee.

2 Nucleonics Laboratory, Abbott Laboratories.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1965 by the Society of Nuclear Medicine.